FOXO TECHNOLOGIES INC. (FOXO) Spending and interest coverage
- R&D / revenue · 12 months: Value 0.96%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value -52.29%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 0.96% | Research and development expense / revenue. Period ending 2026-06-30. $171.56K ÷ $17.86M × 100 ≈ 0.96% |
| Stock-based compensation / revenue · 12 months | -52.29% | Share-based compensation / revenue. Period ending 2026-06-30. $-9.34M ÷ $17.86M × 100 ≈ -52.29% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 171.56K USD | Research and Development Expense |
| Revenue | 17.86M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | -9.34M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -877.76K USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $171.56K | $17.86M | $-9.34M | $-877.76K | (m) | 0.96% | -52.29% | (m) | (m) |
| 2026-03-31 | $188.05K | $18.37M | (m) | $-9.06M | (m) | 1.02% | (m) | (m) | (m) |
| 2025-12-31 | $182.50K | $16.37M | $-164.21K | $-10.33M | (m) | 1.11% | -1.00% | (m) | (m) |
| 2025-09-30 | $147.28K | $14.76M | $-358.77K | $-5.83M | (m) | 1.00% | -2.43% | (m) | (m) |
| 2025-06-30 | $113.99K | $12.41M | $-242.16K | $-5.97M | (m) | 0.92% | -1.95% | (m) | (m) |
| 2025-03-31 | $176.91K | $7.21M | $-192.24K | $-8.13M | (m) | 2.45% | -2.66% | (m) | (m) |
| 2024-12-31 | $312.27K | $4.05M | $-101.73K | $-7.76M | (m) | 7.71% | -2.51% | (m) | (m) |
| 2024-09-30 | $288.00K | $1.34M | $114.00K | $-7.46M | (m) | 21.48% | 8.50% | (m) | (m) |
| 2024-06-30 | $528.00K | $155.00K | $-1.10M | $-9.96M | (m) | 340.65% | -712.90% | (m) | (m) |
| 2024-03-31 | $757.00K | $139.00K | $-401.00K | $-15.97M | (m) | 544.60% | -288.49% | (m) | (m) |
| 2023-12-31 | $901.00K | $145.00K | $381.00K | $-22.19M | (m) | 621.38% | 262.76% | (m) | (m) |
| 2023-09-30 | $1.81M | $453.00K | $10.39M | $-39.37M | $1.05M | 400.00% | 2294.48% | -37.31× | Reported |
| 2023-06-30 | $2.09M | $457.00K | $12.25M | $-44.67M | $1.33M | 456.67% | 2679.87% | -33.56× | Reported |
| 2023-03-31 | $2.75M | $484.00K | $11.71M | $-43.00M | $1.34M | 569.21% | 2418.39% | -32.01× | Reported |
| 2022-12-31 | $3.05M | $511.00K | $11.04M | $-40.17M | $1.44M | 596.28% | 2159.49% | -27.89× | Reported |
| 2022-09-30 | (m) | (m) | (m) | $-13.69M | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | (m) | (m) | (m) | $-5.24M | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | (m) | (m) | (m) | $-4.27M | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | (m) | (m) | $-2.08M | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |